These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9477938)

  • 1. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid.
    Puri BK; Richardson AJ
    Arch Gen Psychiatry; 1998 Feb; 55(2):188-9. PubMed ID: 9477938
    [No Abstract]   [Full Text] [Related]  

  • 2. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid.
    Richardson AJ; Easton T; Gruzelier JH; Puri BK
    Int J Psychophysiol; 1999 Dec; 34(3):333-9. PubMed ID: 10610057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
    Emsley R; Myburgh C; Oosthuizen P; van Rensburg SJ
    Am J Psychiatry; 2002 Sep; 159(9):1596-8. PubMed ID: 12202284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
    Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
    Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
    Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schizophrenic symptoms and dietary intake of n-3 fatty acids.
    Mellor JE; Laugharne JD; Peet M
    Schizophr Res; 1995 Dec; 18(1):85-6. PubMed ID: 8929766
    [No Abstract]   [Full Text] [Related]  

  • 10. Do negative symptoms respond to pharmacological treatment?
    Kane JM; Mayerhoff D
    Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
    [No Abstract]   [Full Text] [Related]  

  • 11. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 13. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.
    Janowsky DS; el-Yousel MK; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Feb; 28(2):185-91. PubMed ID: 4630714
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia.
    Eccleston D; Fairbairn AF; Hassanyeh F; McClelland HA; Stephens DA
    Br J Psychiatry; 1985 Dec; 147():623-30. PubMed ID: 3913486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anticholinergics on positive and negative symptoms in schizophrenia.
    Tandon R; DeQuardo JR; Goodson J; Mann NA; Greden JF
    Psychopharmacol Bull; 1992; 28(3):297-302. PubMed ID: 1480733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone: how good is the evidence for efficacy?
    Mattes JA
    Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of dopamine agonists in the treatment of schizophrenia.
    Corsini GU; Pitzalis GF; Bernardi F; Bocchetta A; Del Zompo M
    Neuropharmacology; 1981 Dec; 20(12B):1309-13. PubMed ID: 7033816
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydergine for schizophrenia.
    Cohen MR; Pary R; Burns R
    J Clin Psychiatry; 1987 Jan; 48(1):39-40. PubMed ID: 3542983
    [No Abstract]   [Full Text] [Related]  

  • 20. Ceruletide: a new drug for the treatment of schizophrenic patients?
    Albus M; Ackenheil M; Münch U; Naber D
    Arch Gen Psychiatry; 1984 May; 41(5):528. PubMed ID: 6372739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.